The "Can't stop the future" conference was organised by the IMA Active division in the splendid setting of the Palazzo di Varignana, just outside Bologna, and at the IMA Active plant in Ozzano dell'Emilia.
The event was dedicated to IMA's latest developments in the field of Continuous Manufacturing of oral solid pharmaceutical forms with international guests from important bodies such as the MIT and the FDA and numerous pharmaceutical companies. The two-day event (26 and 27 September) saw the participation of around 200 pharmaceutical customers from all over the world, in particular from EMEA, but also from the USA and the Far East, who expressed great interest in the latest developments in Continuous Manufacturing. A result that bears witness to IMA's strong commitment to innovation and research into increasingly innovative solutions for the pharmaceutical sector. On the second day, customers had a chance to see the latest innovations offered by IMA Active in pharmaceutical processing and Continuous Manufacturing at the plant of the division in Ozzano dell'Emilia.
Solid dosage forms are still the most common, even though there have not been any significant changes in the last 50 years. However, thanks to a number of pharmaceutical companies and encouragement from regulatory authorities, global companies have started to invest in Continuous Manufacturing. The switch from Batch to Continuous Manufacturing could represent the most important evolution since the advent of the validation and qualification system. The objective of this conference was in fact to spell out the state of the art of Continuous Manufacturing.
The event was introduced by Alberto Vacchi, IMA's Chairman and CEO, who said: “We are very pleased to host numerous pharmaceutical customers from all over the world in the elegant structure of the Palazzo di Varignana and at one of the Group's facilities. For the IMA Group, the world of “Pharma”, with its increasingly demanding challenges, represents an extraordinary accelerator to which we are responding with a huge innovative effort in terms of digitization and automation. Discussing with our customers and hearing their requests helps give direction to our strategic decisions”.
Luca Cavazzini, Sales & Marketing Director of the IMA Active division, added the following comments: “We are very pleased to bring together pharmaceutical companies, regulatory authorities, academics and suppliers to talk about the accelerating process of adoption of Continuous Manufacturing for small molecules and biological products and collaboration between research groups worldwide to facilitate this process. This conference is an excellent opportunity for all of us to guide new technologies and new approaches in the pharmaceutical industry by improving quality, costs and service for the benefit of patients”.
Commitment to technological innovation has always been an element of strong competitive advantage for IMA: ongoing significant investment in R&D (around 4% of consolidated revenue) underlies the Group's growth path and its ability to create value. Suffice to say that the IMA Group owns more than 1,700 patents and patent applications in the world and has launched numerous new machine models over the last years.